Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $562.82, for a total transaction of $4,671,406.00. Following the transaction, the executive vice president directly owned 45,172 shares in the company, valued at $25,423,705.04. The trade was a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

United Therapeutics Trading Up 0.3%

United Therapeutics stock traded up $1.94 during mid-day trading on Thursday, hitting $565.87. 418,827 shares of the company’s stock were exchanged, compared to its average volume of 477,460. The stock has a market cap of $24.02 billion, a P/E ratio of 20.89, a P/E/G ratio of 1.83 and a beta of 0.60. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The stock has a 50 day moving average of $562.18 and a two-hundred day moving average of $510.32.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the previous year, the company earned $6.63 earnings per share. As a group, research analysts predict that United Therapeutics Corporation will post 27.07 EPS for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Torren Management LLC acquired a new stake in shares of United Therapeutics in the fourth quarter valued at about $26,000. Activest Wealth Management grew its position in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the last quarter. Entrust Financial LLC acquired a new stake in shares of United Therapeutics in the fourth quarter valued at about $31,000. International Assets Investment Management LLC lifted its stake in shares of United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 64 shares during the period. Finally, Wilmington Savings Fund Society FSB grew its position in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. UBS Group raised their price target on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Cantor Fitzgerald raised their price target on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Royal Bank Of Canada lowered their price target on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Finally, Raymond James Financial assumed coverage on United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.